CHRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CHRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Coherus Oncology's enterprise value is $271.6 Mil. Coherus Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $197.5 Mil. Therefore, Coherus Oncology's EV-to-Revenue for today is 1.38.
The historical rank and industry rank for Coherus Oncology's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Coherus Oncology was 872.38. The lowest was 0.98. And the median was 3.98.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2025-06-24), Coherus Oncology's stock price is $0.74875. Coherus Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $1.72. Therefore, Coherus Oncology's PS Ratio for today is 0.44.
The historical data trend for Coherus Oncology's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
2.39 | 3.77 | 4.33 | 2.86 | 1.14 |
Coherus Oncology Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
EV-to-Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
2.17 | 1.33 | 1.27 | 1.14 | 1.42 |
For the Biotechnology subindustry, Coherus Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Coherus Oncology's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Coherus Oncology's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 271.621 | / | 197.496 | |
= | 1.38 |
Coherus Oncology's current Enterprise Value is $271.6 Mil.
Coherus Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $197.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (NAS:CHRS) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Coherus Oncology's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 0.74875 | / | 1.715 | |
= | 0.44 |
Coherus Oncology's share price for today is $0.74875.
Coherus Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.72.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Coherus Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Mats Wahlstrom | director | 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401 |
Dennis M Lanfear | director, officer: President and CEO | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Michael Lee Ryan | director | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Mcdavid Stilwell | officer: Chief Financial Officer | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Bryan J Mcmichael | officer: See Remarks | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065 |
Paul Reider | officer: Chief Commercial Officer | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Jill O'donnell-tormey | director | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Charles W. Newton | director | 46 FREDRICK AVENUE, ATHERTON CA 94027 |
Lee Nisley Newcomer | director | 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Vladimir Vexler | officer: Chief Scientific Officer | 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Vincent R Anicetti | officer: Chief, Quality & Compliance | COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Jean-frederic Viret | officer: Chief Financial Officer | ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080 |
Mark Stolper | director | 150 COTNER AVENUE, LOS ANGELES CA 90025 |
Alan C Mendelson | director | ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025 |
From GuruFocus
By GuruFocus News • 05-13-2025
By Marketwired • 04-01-2025
By GuruFocus News • 05-12-2025
By GuruFocus News • 05-12-2025
By GuruFocus News • 05-30-2025
By GuruFocus News • 04-14-2025
By GuruFocus News • 03-07-2025
By Marketwired • 05-05-2025
By GuruFocus News • 05-13-2025
By GuruFocus News • 03-11-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.